Skip to content
OpenCapital
Get started

SELLAS Life Sciences Group, Inc. SLS Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$7.92M+751%
Pfizer logo
PfizerPFE
——
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.8B+674%
Enterprise value$1.7B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%—

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0×0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
SELLAS Life Sciences Group, Inc. (SLS) reported cash provided by (used in) financing activity, including discontinued operation of $44.15M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation increased by 87.2% year-over-year, from $23.58M to $44.15M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a 63.5% compound annual growth rate (CAGR), from $12.07M to $86.3M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.